1 unchanged sentence
Market information
−Removed: Our common stock is publicly traded on the Nasdaq Capital Market under the symbol “MBIO.”
+Added: Our common stock is listed on the Nasdaq Capital Market under the symbol “MBIO.”
Securities Authorized for Issuance Under Equity Compensation Plans
1 unchanged sentence
Holders of Record
−Removed: As of March 8, 2024, there were approximately 71 holders of record of our common stock and one holder of record for our Class A common stock.
+Added: As of March 26, 2025, there were approximately fifty-seven holders of record of our common stock and one holder of record for our Class A common stock.
The actual number of holders of our common stock is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees.
4 unchanged sentences
Recent Sales of Unregistered Securities
+Added: The following list sets forth information as to all unregistered securities we have sold since January 1, 2024, through the date of this Form 10-K:
+Added: June 2024 Private Placement
+Added: On June 19, 2024, we entered into a purchase agreement (the “June 2024 Purchase Agreement”) with an institutional accredited investor, for the issuance and sale of warrants (the “June 2024 Warrants”) to purchase up to 122,600 shares of our common stock.
+Added: Pursuant to the June 2024 Purchase Agreement, we agreed to issue and sell the June 2024 Warrants at an offering price of $20.50 per warrant to purchase one share of common stock.
+Added: The June 2024 Warrants have an exercise price of $20.50 per share (subject to adjustment as set forth in the
+Added: June 2024 Warrants), were exercisable immediately upon issuance and will expire five and one-half (5.5) years from the date on which the June 2024 Warrants become exercisable.
+Added: The June 2024 Warrants contain standard anti-dilution adjustments to the exercise price including for share splits, share dividend, rights offerings and pro rata distributions.
+Added: This offering closed on June 21, 2024, concurrently with a registered direct offering with the same institutional accredited investor that was registered under the Securities Act.
+Added: The gross proceeds to us from the private placement, before deducting placement agent fees and other estimated offering expenses payable by us, were approximately $2.5 million.
+Added: Wainwright & Co., LLC (“Wainwright”) acted as the placement agent in connection with the private placement pursuant to an engagement agreement, between us and Wainwright.
+Added: Wainwright was paid a cash fee equal to 7.0% of the gross proceeds received us in the offerings, a management fee equal to 1.0% of the gross proceeds of the offerings, $75,000 for non-accountable expenses and a clearing fee of $15,950.
+Added: In addition, under the terms of the engagement letter with Wainwright, we issued to Wainwright (or its designees) warrants to purchase up to 7,355 shares of our common stock The warrants issued to Wainwright have substantially the same terms as the June 2024 Warrants, except that the Wainwright warrants will expire five (5) years from the commencement of the sales of the offerings and have an exercise price of $25.625 per share (subject to customary adjustment as set forth in the Wainwright warrants).
+Added: The June 2024 Warrants were offered and sold in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act.
+Added: The investor also represented that it qualified as an “accredited investor” within the meaning of Rule 501 of Regulation D.
+Added: October 2024 Induced Warrant Exercise
+Added: On October 24, 2024, we entered into an inducement offer letter agreement (the “Inducement Letter”) with an institutional accredited investor which held certain outstanding (i) Series A-1 Warrants to purchase up to an aggregate of 337,552 shares of common stock, (ii) Series A-2 Warrants to purchase up to an aggregate of 337,552 shares of common stock, and (iii) Series A-3 Warrants to purchase up to an aggregate of 337,552 shares of common stock, originally issued to the Investor on May 2, 2024 (collectively, the “May 2024 Warrants”).
+Added: The May 2024 Warrants had an exercise price of $11.85 per share.
+Added: Pursuant to the Inducement Letter, the Investor agreed to exercise in full, for cash, the Series A-3 Warrants (the “Existing Warrants”) at the exercise price of $11.85 per share in consideration for our agreement to issue in a private placement (x) new Series B-1 Warrants to purchase 337,552 shares of common stock and (y) new Series B-2 Warrants to purchase 337,552 shares of common stock (collectively, the “New Warrants”).
+Added: In addition, we issued to Wainwright or its designees placement agent warrants to purchase 20,251 shares of common stock.
+Added: The placement agent warrants have the same terms as the Series B-1 Warrants, except that the placement agent warrants have an exercise price equal to $14.815 per share.
+Added: The transactions contemplated by the Inducement Letter closed on October 25, 2024.
+Added: We received aggregate gross proceeds of approximately $4.0 million from the exercise of the Existing Warrants by the investor, before deducting placement agent fees and other expenses payable by us.
+Added: The New Warrants were offered and sold in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act.
+Added: The investor also represented that it qualified as an “accredited investor” within the meaning of Rule 501 of Regulation D.
Issuer Purchases of Equity Securities
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.